- Home
- SQNS vs ANL Comparison
SQNS vs ANL Comparison
Compare SQNS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- ANL
- Stock Information
- Founded
- SQNS 2003
- ANL 2004
- Country
- SQNS France
- ANL Cayman Islands
- Employees
- SQNS N/A
- ANL N/A
- Industry
- SQNS Semiconductors
- ANL
- Sector
- SQNS Technology
- ANL
- Exchange
- SQNS Nasdaq
- ANL Nasdaq
- Market Cap
- SQNS 85.7M
- ANL 79.0M
- IPO Year
- SQNS 2011
- ANL 2023
- Fundamental
- Price
- SQNS $1.88
- ANL $1.85
- Analyst Decision
- SQNS Strong Buy
- ANL Strong Buy
- Analyst Count
- SQNS 1
- ANL 2
- Target Price
- SQNS $7.50
- ANL $9.00
- AVG Volume (30 Days)
- SQNS 65.2K
- ANL 5.4K
- Earning Date
- SQNS 02-11-2025
- ANL 04-15-2025
- Dividend Yield
- SQNS N/A
- ANL N/A
- EPS Growth
- SQNS N/A
- ANL N/A
- EPS
- SQNS 2.00
- ANL N/A
- Revenue
- SQNS $36,762,000.00
- ANL $5,000,000.00
- Revenue This Year
- SQNS N/A
- ANL N/A
- Revenue Next Year
- SQNS $95.51
- ANL N/A
- P/E Ratio
- SQNS $0.98
- ANL N/A
- Revenue Growth
- SQNS 9.36
- ANL N/A
- 52 Week Low
- SQNS $0.95
- ANL $1.83
- 52 Week High
- SQNS $4.28
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- SQNS 27.16
- ANL 40.82
- Support Level
- SQNS $1.87
- ANL $1.85
- Resistance Level
- SQNS $2.18
- ANL $2.20
- Average True Range (ATR)
- SQNS 0.14
- ANL 0.14
- MACD
- SQNS -0.01
- ANL -0.02
- Stochastic Oscillator
- SQNS 6.45
- ANL 25.00
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.